Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas.
brachytherapy
exoresection
surgery
uveal melanoma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Mar 2022
15 Mar 2022
Historique:
received:
12
02
2022
revised:
10
03
2022
accepted:
11
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. This is a single-center observational retrospective cohort study in which we describe clinical outcomes, complications and survival in 35 cases of melanoma of the iris or the ciliary body after a combination of surgery and brachytherapy or brachytherapy alone. Local treatment of the tumor was successful in all cases with surgery and brachytherapy. The most frequent complications were scleromalacia, bullous keratopathy, retinal toxicity, cataracts, hypotonia, and photophobia. There were three cases of recurrence, all of which were found in the group of patients who had received brachytherapy alone, and in one case we had to perform a secondary enucleation due to tumor growth after brachytherapy. At present, only one patient has died during follow-up due to liver metastases six years after the start of treatment. In carefully selected patients, this approach can be effective and safe, as long as a close follow-up is carried out after surgery.
Identifiants
pubmed: 35329942
pii: jcm11061616
doi: 10.3390/jcm11061616
pmc: PMC8956023
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):101-8
pubmed: 16111577
Ophthalmic Surg. 1988 Nov;19(11):774-80
pubmed: 3222038
Exp Ther Med. 2021 Dec;22(6):1428
pubmed: 34707709
Middle East Afr J Ophthalmol. 2010 Jul;17(3):210-6
pubmed: 20844676
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1236-40
pubmed: 16505064
Ann ICRP. 2012 Feb;41(1-2):1-322
pubmed: 22925378
Dev Ophthalmol. 2012;49:66-80
pubmed: 22042014
Prog Retin Eye Res. 2018 Sep;66:187-199
pubmed: 29571968
Eye (Lond). 2021 Oct;35(10):2754-2762
pubmed: 33235338
JAMA Ophthalmol. 2017 Jul 1;135(7):805-806
pubmed: 28448661
J Contemp Brachytherapy. 2021 Jun;13(3):358-364
pubmed: 34122577
Br J Ophthalmol. 2014 Jun;98(6):775-9
pubmed: 24568869
Eye (Lond). 2021 May 3;:
pubmed: 33941875
J Contemp Brachytherapy. 2021 Feb;13(1):46-50
pubmed: 34025736
Eye (Lond). 2013 Feb;27(2):163-71
pubmed: 23196647
Arch Ophthalmol. 2001 Jul;119(7):1067-8
pubmed: 11448330
Med Clin North Am. 2021 May;105(3):531-550
pubmed: 33926645
JAMA Ophthalmol. 2016 Jul 1;134(7):734-40
pubmed: 27123792
Surv Ophthalmol. 2017 May - Jun;62(3):302-311
pubmed: 28062196
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
Ophthalmology. 2006 May;113(5):865-73
pubmed: 16530837
Brachytherapy. 2014 Jan-Feb;13(1):1-14
pubmed: 24373763
Surg Oncol. 2021 Mar;36:113-114
pubmed: 33340808
Br J Ophthalmol. 1998 Mar;82(3):213-8
pubmed: 9602614
Int Ophthalmol Clin. 2006 Winter;46(1):81-93
pubmed: 16365557
BMC Ophthalmol. 2021 Nov 2;21(1):385
pubmed: 34727878